• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Benefits of non –vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention
The last decade has produced a large body of robust randomized controlled trial (RCT) data investigating the use of non –vitamin K antagonist oral anticoagulants (NOACs) in nonvalvular atrial fibrillation (AF).1–4 Compared with warfarin, dabigatran and apixaban have been found to reduce the combined outcome of stroke and systemic embolism. In addition, apixaban and edoxaban significantly reduce major bleeding. Fu rthermore, a pooled meta-analysis has demonstrated superior efficacy and overall safety of the NOACs.
Source: Heart Rhythm - January 15, 2017 Category: Cardiology Authors: Jay A. Montgomery, Gregory F. Michaud Tags: Editorial Commentary Source Type: research

Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation
Little is known about the clinical benefit of a non–vitamin K antagonist oral anticoagulant compared with warfarin in elderly Chinese patients with atrial fibrillation (AF).
Source: Heart Rhythm - September 18, 2015 Category: Cardiology Authors: Pak-Hei Chan, Duo Huang, Jojo Hai, Wen-Hua Li, Li-Xue Yin, Esther W. Chan, Ian C.K. Wong, Chu-Pak Lau, Chern-En Chiang, Jun Zhu, Hung-Fat Tse, Chung-Wah Siu Source Type: research

Stroke Prevention Using Dabigatran in the Very Elderly with Atrial Fibrillation
Little is known about the clinical benefit of a non-vitamin K antagonist oral anticoagulant (NOAC) compared with warfarin in elderly Chinese patients with atrial fibrillation (AF).
Source: Heart Rhythm - September 18, 2015 Category: Cardiology Authors: Pak-Hei CHAN, Duo HUANG, Jojo HAI, Wen-Hua LI, Li-Xue YIN, Esther W. CHAN, Ian C.K. WONG, Chu-Pak LAU, Chern-En Chiang, Jun ZHU, Hung-Fat TSE, Chung-Wah SIU Source Type: research